Note to myself: After I reviewed the article mentioned below, I found it unhelpful. I write this just to remind myself. Therefore, I have only included the abstract in this post.
The abstract does have the percentages of Mild Cognitive Impairment by age.
In this post I link to and excerpt only the abstract from the American Academy of Neurology‘s 2018 Practice guideline update summary: Mild cognitive impairment [PubMed Abstract] [Full Text HTML] [Full Text PDF]. Neurology. 2018 Jan 16; 90(3): 126–135.
Here is the abstract:
Objective: To update the 2001 American Academy of Neurology (AAN) guideline on mild cognitive impairment (MCI).
Methods: The guideline panel systematically reviewed MCI prevalence, prognosis, and treatment articles according to AAN evidence classification criteria, and based recommendations on evidence and modified Delphi consensus.
Results: MCI prevalence was 6.7% for ages 60-64, 8.4% for 65-69, 10.1% for 70-74, 14.8% for 75-79, and 25.2% for 80-84. Cumulative dementia incidence was 14.9% in individuals with MCI older than age 65 years followed for 2 years. No high-quality evidence exists to support pharmacologic treatments for MCI. In patients with MCI, exercise training (6 months) is likely to improve cognitive measures and cognitive training may improve cognitive measures.
Major recommendations: Clinicians should assess for MCI with validated tools in appropriate scenarios (Level B). Clinicians should evaluate patients with MCI for modifiable risk factors, assess for functional impairment, and assess for and treat behavioral/neuropsychiatric symptoms (Level B). Clinicians should monitor cognitive status of patients with MCI over time (Level B). Cognitively impairing medications should be discontinued where possible and behavioral symptoms treated (Level B). Clinicians may choose not to offer cholinesterase inhibitors (Level B); if offering, they must first discuss lack of evidence (Level A). Clinicians should recommend regular exercise (Level B). Clinicians may recommend cognitive training (Level C). Clinicians should discuss diagnosis, prognosis, long-term planning, and the lack of effective medicine options (Level B), and may discuss biomarker research with patients with MCI and families (Level C).
Copyright © 2017 American Academy of Neurology.